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Letters to the EditorIs transient elastography inaccurate in chronic hepatitis B and
non-alcoholic fatty liver disease?To the Editor:
We read with great interest the study by Gaia and colleagues on
the accuracy of transient elastography (TE) in patients with
chronic hepatitis B (CHB) and non-alcoholic fatty liver disease
(NAFLD) [1]. The authors casted doubt on the reliability of TE
based on two provocative observations: (i) the median liver stiff-
ness measurement (LSM) was higher in CHB patients with severe
ﬁbrosis (F3) than in those with histological cirrhosis (F4); and (ii)
NAFLD patients with advanced ﬁbrosis (F3) and severe steatosis
(>33%) had similar LSM to those with milder ﬁbrosis (F0-1) but
less steatosis. We believe that these observations should be inter-
preted carefully.
Based on the previous validation studies of larger sample
sizes, serum alanine aminotransferase (ALT) level is one of the
major confounding factors of LSM [2,3]. Patients with high ALT
will have increased LSM independent of the ﬁbrosis stage, and
LSM might be deceivingly high to even a cirrhotic range in
patients of severe acute exacerbation of CHB [4]. Therefore, LSM
should be interpreted in the context of ALT level. In the current
study, the median ALT level was 70 IU/L among 70 CHB patients,
and it was as high as 464 IU/L in one patient. If patients with F3
ﬁbrosis have higher ALT levels than those with F4 ﬁbrosis, the
LSM might have been misinterpreted. To prove the accuracy of
LSM, the inﬂuence of ALT should be taken into consideration.
One could present the box plots of LSM versus Metavir ﬁbrosis
stage in CHB patients after stratifying into normal ALT, ALT 1-
5x upper limit of normal (ULN) and ALT >5 ULN.
Contrary to previous reports on NAFLD and chronic hepatitis
C, the authors observed an underestimation of LSM in patients
with steatosis >33% [1]. However, it was based on an over-simpli-
ﬁed statistical analysis, because the real relationship between
steatosis and LSM could not be demonstrated by mean LSM val-
ues only. Instead, upon detailed assessment of the effect of stea-
tosis on LSM in patients with different ﬁbrosis stages (Fig. 4 in the
paper), there was no evidence that hepatic steatosis was associ-
ated with lower LSM in patients within the same ﬁbrosis stage
[1]. In our previous study including 246 NAFLD patients, the
mean LSM for F0, F1, F2, F3, and F4 ﬁbrosis was 5.7, 6.8, 7.8,
11.8, and 25.1 kPa, respectively [5]. Again, the groups with higher
hepatic steatosis did not have lower LSM (Fig. 1).
Conﬂict of interest
Grace L.H. Wong has served as a speaker for Echosens. Vincent
W.S. Wong has served as a speaker for Roche, Novartis Pharma-
ceuticals and Abbott Diagnostic. Henry L.Y. Chan has served asJournal of Hepatology 20an advisory board member for Bristol-Myers Squibb, F. Hoffmann
La Roche, Novartis Pharmaceutical and Abbott Diagnostic.
References
[1] Gaia S, Carenzi S, Barilli AL, et al. Reliability of transient elastography for the
detection of ﬁbrosis in non-alcoholic fatty liver disease and chronic viral
hepatitis. J Hepatol 2011;54:64–71.
[2] Wong GL, Wong VW, Choi PC, et al. Assessment of ﬁbrosis by transient
elastography compared with liver biopsy and morphometry in chronic liver
diseases. Clin Gastroenterol Hepatol 2008;6:1027–1035.
[3] Chan HL, Wong GL, Choi PC, et al. Alanine aminotransferase-based algorithms
of liver stiffness measurement by transient elastography (Fibroscan) for liver
ﬁbrosis in chronic hepatitis B. J Viral Hepat 2009;16:36–44.
[4] Wong GL, Wong VW, Choi PC, et al. Increased liver stiffness measurement by
transient elastography in severe acute exacerbation of chronic hepatitis B. J
Gastroenterol Hepatol 2009;24:1002–1007.
[5] Wong VW, Vergniol J, Wong GL, et al. Diagnosis of ﬁbrosis and cirrhosis using
liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology
2010;51:454–462.
Grace Lai-Hung Wong
Vincent Wai-Sun Wong
Henry Lik-Yuen Chan⇑
Institute of Digestive Disease and Department of Medicine and
Therapeutics, The Chinese University of Hong Kong, 9/F Prince of
Wales Hospital, 30-32 Ngan Shing Street, Shatin, Hong Kong, China
 Tel.: +852 2632 3593; fax: +852 2637 3852
E-mail address: hlychan@cuhk.edu.hk (H. L.-Y. Chan)
S1
S2
S3
F1F0 F2 F3 F4
Pe
rc
en
ta
ge
 (%
)
0
10
20
30
40
50
60
70
80
90
100
14
21
35
26
27
22
25
13
7
12
14
5
4
12
9
Fig. 1. Distribution of the steatosis and ﬁbrosis of the 246 NAFLD patients [5].11 vol. 55 j 497–502
